ISBN: 978-81-985724-3-1

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

# Precision Oncology: Innovations in Diagnosis, Drug Delivery, And Patient Care




**Published By – Nexus Knowledge Publication**

**(Imprint of AKT Multitask Consultancy)**

**Bilaspur, Chhattisgarh, India, 495006**

**www.aktmultitask.com**

DOI 10.5281/zenodo.17199086

Chapter- 6

# INTRODUCTION TO PRECISION ONCOLOGY

**DANJU DAHARIA**
Kamla Institute of Pharmaceutical Sciences, Bhilai
Email: anjudaharia055@gmail.com

**LOKKANYA DEWANGAN**
Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai
Email; lokkanyadewangan@gmail.com

**TUSAR VERMA**
Shri Shankaracharya Institute of Pharmaceutical Sciences, and Research, Bhilai
Email: tv121719951996@gmail.con

**ALKA VERMA**
Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai
Email: alkaakverma@gmail.com

**SWAPNIL DESHMUKH**
Kamla Institute of Pharmaceutical Science, Bhilai
Email: swapnilpharma020@gmail.com

ISBN: 978-81-985724-3-1



*Chapter 6…*

# TARGETED THERAPIES IN PERSONALIZED TREATMENT

**ANJU DAHARIA**
Kamla Institute of Pharmaceutical Sciences, Bhilai
Email: anjudaharia055@gmail.com

**LOKKANYA DEWANGAN**
Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai
Email; lokkanyadewangan@gmail.com

**TUSAR VERMA**
Shri Shankaracharya Institute of Pharmaceutical
Sciences, and Research, Bhilai
Email: tv121719951996@gmail.con

**ALKA VERMA**
Shri Shankaracharya Institute of Pharmaceutical Sciences, and Research, Bhilai
Email: alkaakverma@gmail.com

**SWAPNIL DESHMUKH**
Kamla Institute of Pharmaceutical Science, Bhilai
Email: swapnilpharma020@gmail.com

ISBN: 978-81-985724-3-1


Targeted therapies are a type of cancer therapy aimed at disrupting certain life cycle processes vital to the growth, survival and cellular division of the tumor. As compared to traditional chemotherapy, which indiscriminately attacks high-dividing cells, targeted therapies can target genetic or protein abnormalities specific to cancer cells and decrease the systemic toxicity of treatment and enhances treatment efficacy. One of the largest categories of targeted therapies is kinase inhibitors that suppress uncontrolled proliferation and survival of cancer by targeting enzyme dysregulation such as EGFR, BRAF, and ALK. On the one hand, these inhibitors, which are available in various generations, are chosen according to the molecular profiling in accordance with the specifics of tumors in the patient, which guarantees precision medicine strategies that will enhance the results.

Targeted therapies have revolutionized the treatment of cancers including non-small-cell lung cancer (NSCLC), melanoma, breast cancer and colorectal cancer. EGFR and ALK inhibitors prevent important signaling pathways and increase apoptosis and decrease tumor growth in NSCLC. BRAF/MEK inhibitors used in melanoma use the MAPK pathway and control the proliferation, whereas antibodies against HER2 and antibody-drug conjugates are used against HER2-positive breast cancer to improve the survival. EGFR-targeted therapy is effective in patients with colorectal cancer and RAS wild-type tumors where molecular testing and individualized choice of treatment options should be preferred in order to reach the best clinical outcomes.

A significant problem is resistance to targeted therapies, though. Secondary mutations, switching of pathways, or phenotypic modifications, including epithelial-to-mesenchymal transition, enable cancer cells to evade treatment. Next-generation inhibitors such as osimertinib of EGFR T790M mutations and lorlatinib of resistant ALK mutations have been developed to counter the resistance and provide more-durable responses. There is a tendency to use these agents in series or combined with other therapies, in order to sustain its effectiveness and tumor avoidance.

Combination therapies with targeted therapy and chemotherapy/immunotherapy are better therapies that improve effectiveness in treating cancer by destroying cancer in multiple ways. Tumors can be sensitized to targeted agents by chemotherapy and the immune system of the patient can be utilized through immune therapy with targeted drugs enhancing the immune recognition and infiltration. These multi-pronged modalities stem out the chances of resistance, enhance clinical responses, and extend survival. Yet they need special attention to toxicity,

ISBN: 978-81-985724-3-1


optimization of sequencing, and patient selection along molecular profiling in order to utilize the benefits to the fullest extent and reduce the negative effects.

## 6.1. KINASE INHIBITORS AND PATHWAY BLOCKERS (EGFR, BRAF, ALK, ETC.)

Targeted therapies are an advanced form of anticancer therapy that targets a specific molecule, gene, or signaling pathway that is indispensable to the survival, growth and dissemination of cancerous cells. As opposed to traditional chemotherapy, which indiscriminately targets the high dividing cells, such as healthy ones, targeted therapies are specific to cancer cells by attacking molecular defects. This accuracy lowers systemic toxicity, increases the therapeutic index and the ability to personalize treatment plans according to the tumor profile of a patient. The invention of such therapies depends on the use of molecular diagnostics, including genomic profiling and biomarker analysis, that would help to screen the patient as the most likely getter of certain targeted agents. As targeted therapies act upon the underlying molecular pathogenesis of cancer and not its symptoms, they are more effective, associated with reduced adverse events and can also be used in combination regimens with chemotherapy or immunotherapy to achieve better results.

- ***Kinase Inhibitors***

Kinases are enzymes responsible in cell signaling through the catalysis of phosphorylation or the addition of phosphate to proteins. This change is essential to regulate cellular functions like growth, differentiation, survival, metabolism and apoptosis. Dysregulation of kinase activity in cancers is caused by mutation, overexpression, or gene rearrangements in most cases resulting in unregulated proliferation and resistance to cell death. Since kinases are hubs of critical signaling pathways, they make very attractive targets of cancer treatment. These aberrant signals are specifically blocked by kinase inhibitors, both small molecule and monoclonal antibody, with the effect of preventing tumor progression without damaging normal cells.

ISBN: 978-81-985724-3-1






**Figure 1:** Kinase Inhibitors

**Source: (https://www.caymanchem.com/news/kinase-inhibitors?srsltid=AfmBOoqERph2V2yJioFtly61z5mYEFIIfs-ebaKvzmAHT0xVKBgSM7-m)**

### 1. EGFR (Epidermal Growth Factor Receptor) Inhibitors

EGFR is also a receptor tyrosine kinase which controls the cell proliferation, cell survival and cell differentiation. EGFR may be overexpressed or mutated in cancers like non-small-cell lung cancer (NSCLC), colorectal cancer, and head-and-neck cancers and leads to unregulated signaling and tumor growth.

- **Drugs and Generations:**
  - ***First-generation:*** Erlotinib, Gefitinib – These drugs competitively inhibit the ATP-binding site of EGFR, preventing phosphorylation and downstream signaling.
  - ***Second-generation:*** Afatinib – Irreversibly inhibits EGFR, including some resistance mutations.

ISBN: 978-81-985724-3-1


- ***Third-generation:*** Osimertinib – Specifically targets T790M EGFR mutations, a common mechanism of acquired resistance to earlier drugs.

- **Mechanism of Action:** EGFR inhibitors bind to the tyrosine kinase domain of the receptor, blocking activation of downstream pathways such as:
  - **RAS/RAF/MEK/ERK pathway:** Controls cell proliferation.
  - **PI3K/AKT pathway:** Regulates survival and apoptosis.

Blockage of these pathways causes slowed tumor cells growth, accelerated programmed cell death and in most cases tumor regression. Response to clinical therapy is contingent on the presence of certain EGFR mutations, and therefore genomic profiling is important in selecting therapy.

**2. BRAF Inhibitors**

BRAF is a serine/threonine kinase that is a part of the MAPK (Mitogen-Activated Protein Kinase) pathway, which is in charge of cell growth and differentiation as well as survival. BRAF V600E mutation leads to constitutive BRAF pathway activation, which leads to uncontrolled proliferation. BRAF mutations are common in thyroid cancer, melanoma and colorectal cancer.

- **Drugs:**
  - Vemurafenib, Dabrafenib – These selectively inhibit the mutated BRAF kinase.
- **Mechanism of Action:** BRAF inhibitors prevent the inappropriate signaling of the MAPK pathway, arresting the cells in the cell cycle and causing apoptosis. To ensure avoidance of resistance due to pathway reactivation, BRAF inhibitors are typically used together with MEK inhibitors, the same pathway downstream drug, and increase efficacy and patient response time.

**3. ALK (Anaplastic Lymphoma Kinase) Inhibitors**

ALK is a receptor tyrosine kinase that takes part in cell survival and proliferation. Gene rearrangements or fusions of ALK occur in subsets of NSCLC, and in a few lymphomas, leading to sustained oncogenic signaling.

- **Drugs and Generations:**
  - ***First-generation:*** Crizotinib – Effective in ALK-positive tumors but prone to resistance.

ISBN: 978-81-985724-3-1


- ***Second-generation:*** Alectinib – Overcomes certain resistance mutations and has better CNS penetration.
- ***Third-generation:*** Lorlatinib – Targets resistant ALK mutations, including those unresponsive to earlier inhibitors.

- **Mechanism of Action:**

ALK inhibitors suppress signaling through pathways including:

- **PI3K/AKT:** Promotes survival.
- **RAS/RAF/MEK/ERK:** Promotes proliferation.
- **JAK/STAT:** Promotes growth and immune evasion.

This blockade reduces tumor proliferation and induces apoptosis. Sequential therapy with newer generation inhibitors is often necessary to overcome acquired resistance.

## 6.2. FDA-APPROVED TARGETED THERAPIES BY TUMOR TYPE

Targeted therapies have radically transformed the oncology paradigm, with the emphasis on traditional, widely cytotoxic chemotherapy giving way to the necessity of precision medicine directed by the molecular nature of a specific patient tumor. In contrast to the traditional chemotherapy, which destroys all the rapidly dividing cells, tumors, or normal ones, targeted therapies are selective; they target a specific molecule, receptor, or signaling pathway that is vital to tumor growth, survival, metastasis, and angiogenesis. Such specificity enables a better control of the tumor and at the same time reduces collateral damage of normal tissues, thereby, lowering the side effects and enhancing the overall quality of life of the patients. Targeted therapies represent the ideals of personalized medicine since they employ treatment regimens that are explicitly based on the biology of the specific disease in a person, as opposed to an overview strategy.

Cancer biology is complex and heterogeneous and has led to the evolution and the acceptance of targeted therapies across a wide range of tumor types. Molecular profiling and biomarker testing and genetic profiling are essential in determining whether the patient who carries tumors with actionable mutations or certain protein expression is suitable to receive such therapies. An example is that medications that EGFR mutations in non small cell lung cancer, or HER2 amplifications in breast cancer are used only once these particular molecular changes are

ISBN: 978-81-985724-3-1


present. This strategy is effective in making sure that patients are provided with interventions that have the maximum probability of being effective without undergoing unwarranted treatments that would not benefit them much. Because of this, molecular diagnostics and biomarker-based approaches have taken a central stage in precision oncology, informing clinical decision-making and streamlining therapeutic performance.

FDA-approved targeted therapies combined with accurate diagnostics have created a new paradigm in cancer therapy, in which therapy is tailored to optimally achieve effectiveness and minimally toxicity. This is a combined strategy that helps to not only better patient outcomes through provision of the most appropriate interventions, but also to improve resource use in healthcare through targeting treatment to those with the highest potential to respond. Moreover, the recent emergence of new targeted agents and combination therapies continues to widen the therapeutic repertoire that can be utilized to achieve precision oncology and overcome resistance mechanisms and maximize long-term patient survival. Integrating treatment plans with the molecular and genetic phenotype of every tumor, this model is the highest level of personalized medicine in oncology where treatment is scientifically customized, clinically efficient, and tailored to maximize treatment utility and patient quality of life.

## Lung Cancer

- **Non-Small Cell Lung Cancer (NSCLC):** NSCLC is a cancer with one of the most widely investigated targeted therapies because of its high incidence and characterized drivers of the disease. Important molecular targets are:



**Figure 2:** Lung Cancer

**Source: (https://www.parkwaycancercentre.com/lk/news-events/news-articles/news-articles-details/advanced-lung-cancer-diagnosis-treatment)**

- **EGFR (Epidermal Growth Factor Receptor) Mutations:** EGFR is a receptor tyrosine kinase involved in regulating cell proliferation, survival, and apoptosis. Mutations in EGFR, particularly exon 19 deletions or L858R point mutations, result in constitutive activation of downstream signaling pathways, including RAS/RAF/MEK/ERK and PI3K/AKT, driving tumor growth.
    - **FDA-approved drugs:** Erlotinib, Gefitinib, Afatinib, Osimertinib.
    - **Mechanism:** These drugs inhibit EGFR tyrosine kinase activity, reducing uncontrolled proliferation and promoting apoptosis in EGFR-mutant tumor cells.
- **ALK (Anaplastic Lymphoma Kinase) Rearrangements:** ALK fusions, such as EML4-ALK, lead to constitutive kinase activity, activating pathways like PI3K/AKT, RAS/RAF/MEK/ERK, and JAK/STAT, which drive oncogenesis.
    - **FDA-approved drugs:** Crizotinib (first-generation), Alectinib (second-generation), Lorlatinib (third-generation).
    - **Clinical relevance:** Molecular testing using FISH, IHC, or NGS is essential to detect ALK rearrangements, ensuring only patients with ALK-positive tumors receive these inhibitors.

Targeted therapy in NSCLC has significantly improved response rates and progression-free survival compared with traditional chemotherapy, particularly when molecular selection is used.

**Melanoma**

- **BRAF-Mutant Melanoma:** BRAF genes are mutated and most are V600E which constitutively activates the MAPK pathway to result in uncontrolled growth.

ISBN: 978-81-985724-3-1




**Figure 3:** Melanoma

**Source: (https://en.wikipedia.org/wiki/Melanoma)**

- **BRAF inhibitors:** Vemurafenib, Dabrafenib - are specific inhibitors of mutant BRAF kinase, which prevents MAPK signaling and promotes apoptosis.
- **MEK inhibitors:** Cobimetinib, Trametinib - the MEK1/2 downstream inhibitors are effective at augmenting the impact of BRAF inhibitors and slowing down resistance.

- **Combination therapy:** BRAF and MEK inhibitors are often co-administered to reduce compensatory pathway activation and improve durability of response.
- **Molecular testing:** Only patients with confirmed BRAF V600 mutations benefit from these therapies, highlighting the importance of precision diagnostics in melanoma management.

**Breast Cancer**

- **HER2-Positive Breast Cancer:** HER2 (Human Epidermal Growth Factor Receptor 2) amplification or overexpression is witnessed in 15-20 per cent of breast cancer and is linked with aggressive cancer. Oncogenic signaling is inhibited with the help of HER2-targeted therapies to enhance survival.

ISBN: 978-81-985724-3-1





**Figure 4:** Breast Cancer

**Source: (https://en.wikipedia.org/wiki/Breast_cancer)**

- **Monoclonal antibodies:** Trastuzumab, Pertuzumab - extracellular binding to HER2 and inhibition of receptor dimerization and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling.
- **Antibody-drug conjugates (ADCs):** Ado-trastuzumab emtansine - provides cytotoxic reagents directly to the cells with the HER2-positive phenotype.

➢ **Clinical significance:** The application is only applicable in patients with confirmed cases of HER2 overexpression or gene amplifications, and, in this respect, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) tests are paramount. Targeted HER2 therapy has significantly increased life expectancy and changed prognosis in the HER2-positive breast cancer.

**Colorectal Cancer**

➢ **EGFR-Targeted Therapy in RAS Wild-Type Tumors:** EGFR is one of the primary motivational factors of colorectal cancer development, yet only in patients with RAS wild-type tumors, its inhibition is effective. KRAS or NRAS gene mutations bypass EGFR-induced downstream signaling and make EGFR inhibitors inefficient.




**Figure 5:** Colorectal Cancer

**Source: (https://link.springer.com/rwe/10.1007/978-3-319-90761-1_80-1)**

- **FDA-approved drugs:** Cetuximab, Panitumumab monoclonal antibody that inhibits proliferation and induces apoptosis, extracellularly blocks EGFR.
- **Molecular profiling:** RAS status assessment is required prior to receiving therapy to determine those patients who may respond.

These therapies by focusing on EGFR in the right patient slow the tumor disease progression and enhance clinical responses, representing the principle of precision oncology of matching the therapy to the genetic profile of the tumor."

➢ **Key Considerations in Precision Oncology**

- **Molecular Testing:** Molecular profiling in a comprehensive way is the main driver of precision oncology because it allows the detection of actionable mutations, gene amplifications, and structural rearrangements that promote tumor development. Next-generation sequencing (NGS) techniques allow a comprehensive genomic view of a large number of alterations present at once whereas polymerase chain reaction (PCR) is essential in detection of specific mutations with high sensitivity. The expression of proteins can be evaluated by immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) is commonly used to detect chromosomal defects. All of these approaches create the foundation of patient stratification and therapeutic decision-making.
- **Individualized Therapy:** Treatments are chosen based upon the molecular and genetic features of the specific tumor, and care is made not to generalize but rather to match

ISBN: 978-81-985724-3-1


therapy with the specific disease profile of the patient. The method is most likely to result in clinical benefit with minimal unwarranted toxicity and side effects. As an example, EGFR-mutated patients can receive EGFR-inhibitors, and HER2-amplified patients are provided with HER2-targeted therapies. Individualized therapy paves the way to real personalization by addressing the unique vulnerabilities of tumours.

- **Combination Strategies:** Resistance to single-agent targeted treatment is a big issue in oncology. To mitigate this, combination regimens in which targeted agents are used together with chemotherapy, immunotherapy or with other targeted drugs are becoming more widely used in precision oncology. The combinations of this act to target tumors in several ways, minimize the chances of resistance, and generate long-term responses. An example of such a combination is the use of immune checkpoint inhibitors together with targeted therapy, which has demonstrated potential in increasing long-term disease control in a variety of cancers.
- **Varied clinical consequences:** The adoption and adaptation of targeted therapies in clinical practice by regulatory authorities such as the U.S. FDA has changed the face of cancer treatment. Biomarker-driven therapies have shown that patients undergoing such treatment have a much better outcome with a better response rate, prolonged progression-free survival and overall survival rates than a traditional treatment method. These achievements demonstrate the potential to change the landscape of precision oncology and convert previously incurable cancers into controlled or even curable diseases.

## 6.3. MECHANISMS OF RESISTANCE AND NEXT-GENERATION INHIBITORS

Targeted therapies are revolutionizing the treatment of cancer by selectively targeting molecules and signaling pathways necessary to growth and survival of tumors. Nonetheless, the efficacy of the therapies is often affected by the resistance of the cancer cells. The cancer cells are highly genetically unstable and adaptive in nature as compared to normal cells, and thus respond to the selection pressure induced by specific therapy. Resistance may occur in a variety of ways, such as secondary mutations in the target protein, the activation of other signaling pathways, epigenetic changes, or phenotypic plasticity, whereby tumor cells can survive therapy. Such adaptations are associated with decreased drug efficacy, disease progression, and disease relapse that becomes a major challenge to sustained clinical benefit.

ISBN: 978-81-985724-3-1


To design next-generation therapeutic inhibitors capable of surmounting such challenges, an understanding of the molecular and cellular foundation of therapeutic resistance is absolutely necessary. Researchers are developing new agents that can inhibit resistance pathways, inhibit the compensatory signaling, or integrate several therapeutic interventions to deny break-even mechanisms. Moreover, biomarker-based strategies enable clinicians to track the development of resistance in real time and change treatment regimens. Next-generation inhibitors would recreate long-term activity, extend patient survival, and continue to improve the promise of precision oncology by merging knowledge of resistance mechanisms into drug design and clinical practice.

**Common resistance mechanisms:**

- **Secondary Mutations:** One of the most prevalent types of resistance can be the secondary or acquired mutations in the target protein itself. Such mutations usually take place at the drug-binding site or close to it, and this inhibitor is unable to bind to its target effectively. Here, to illustrate, in non-small cell lung cancer (NSCLC) patients with EGFR mutations, the T790M mutation develops in a significant proportion of patients that receive first-generation EGFR inhibitors including erlotinib or gefitinib. This mutation changes the binding site of ATP of EGFR, decreasing the ability of the drug to bind and making therapy ineffective. Likewise, mutations in the ALK-positive NSCLC, including L1196M or G1202R, can be resistant to first-generation ALK inhibitors, including crizotinib. These late mutations prove the dynamic essence of tumor evolution and the necessity of therapies that will be able to overcome these adaptive alterations.
- **Note:** Activation of Alternative Pathways Cancer cells do not rely on just one signaling pathway to survive; they are frequently redundant or parallel pathways that can take over in the event that the original pathway is inhibited. It is through this phenomenon that the tumors can overcome the therapeutic blockade and proceed to proliferate. As an example, even in the presence of EGFR inhibition, MET amplification in EGFR-mutant NSCLC can stimulate cell growth. Equally, PI3K/AKT/mTOR or MAPK pathways activation in different cancers can be used as escape mechanisms as they help tumors to survive even after targeted therapy. This pathway redundancy reiterates that cancer signaling networks are complicated and requires mechanisms that either act in concert or proactively prevent compensatory responses.

ISBN: 978-81-985724-3-1


- **Phenotypic Changes:** Adaptive phenotypic changes are also a method of cancer cells becoming resistant. Among them is epithelial-to-mesenchymal transition (EMT) in which cancer cells change their proliferative epithelial identity into an invasive mesenchymal identity. This change is linked to an elevated metastatic capability and decreased responsiveness to drugs. Phenotypic changes that do not involve changes in apoptotic signaling can also reduce the efficacy of targeted therapies e.g. metabolic reprogramming or epigenetic modifications. These alterations indicate the impressive plasticity of tumor cells and present a substantial challenge of the long-term efficacy of treatment.
- **Next-Generation Inhibitors:** In response to resistance mechanisms, new generations of targeted therapies are being developed that help either overcome a particular resistance mutation or block by pass signaling pathways. The intent of these medications is to afford long-term effectiveness even in cancer cells that have developed resistance against previous-generation treatment.
    - **Osimertinib:** Osimertinib is the third-generation EGFR inhibitor that is specifically active in NSCLC tumors that contain the resistance mutation T790M. Significantly, it only attacks mutant EGFR and not wild-type EGFR, minimizing off-target toxicity and enhancing tolerability.
    - **Lorlatinib:** The next-generation ALK inhibitor that is useful against tumors with resistant ALK mutations resistant to the initial or second generation ALK inhibitors, providing a critically important treatment option with patients who have developed refractory ALK-positive NSCLC.

Clinicians can enhance the longevity of response by predicting resistance and designing inhibitors with the critical strategies to address these mechanisms. The next-generation inhibitors are commonly administered sequentially, or following chemotherapy, immunotherapy, or other targeted therapies, to slow or reverse the development of resistance.

## 6.4. COMBINATION STRATEGIES WITH CHEMOTHERAPY OR IMMUNOTHERAPY

Targeted therapies have revolutionized the field of oncology because they specifically inhibit molecular pathways that are needed to promote tumor growth and survival. These agents in spite of their specificity may have problems using them as monotherapy. A large proportion of

the patients respond partially, and there is adaptive resistance to tumors by alternative signaling pathways or genetic mutations that ultimately results in progression or relapse of the disease. These constraints underscore the importance of adjunct ARY treatment modalities capable of dealing with tumor heterogeneity, and the dynamism of cancer biology.

To address these obstacles, the combination of targeted therapies and chemotherapy or immunotherapy has garnered a lot of interest. Chemotherapy may simply kill fast dividing cancerous cells, and immunotherapy may evoke the immune system of the patient to identify and kill tumor cells. These combination strategies, when combined with specific agents, have the potential to address cancer in a multifactorial manner and possibly increase overall effectiveness of treatment. Clinical trials indicated that the strategies could extend survival, enhance response rate, and decrease the chances of resistance and provide a stronger and longer lasting therapeutic effect on the patient regardless of the cancer type.

### Combination with Chemotherapy

Chemotherapy has played a historic role in the field of oncology, but its main effect is non-selective cytotoxicity, which is directed against actively dividing cells. Although successful, chemotherapy may, in some cases, be ineffective because cancer cells may switch to other survival mechanisms. Cytokine therapy can be improved by incorporation of target therapies with chemotherapy to influence the treatment outcomes by sensitizing the tumor cells to cytotoxic effects.

As a case example, the use of HER2-targeted inhibitors like trastuzumab or pertuzumab together with conventional chemotherapy regimens has become the norm in the HER2-positive breast cancer. The agents are directed against HER2-mediated signaling pathways that induce cell survival and proliferation. This suppression renders cancer cells more susceptible to the effects of chemotherapy (or mitotic block) on their DNA damage or mitosis, which in turn enhances the response rates, progression-free survival, and the overall survival. Basically, chemotherapy is a mass production cytotoxic attack, whereas targeted therapies have selective down regulation of important oncogenic pathways and lead to synergistic anti-tumor activity.

Further, it can be used in combination with chemotherapy to overcome intrinsic resistance to some tumors. Partially responsive tumors could become fully responsive when supportive survival pathways are simultaneously inhibited, and hence, lower the chances of disease progression.

ISBN: 978-81-985724-3-1


### Combination with Immunotherapy

Immunotherapy is a new paradigm shift in the treatment of cancer, the goal of which is to unite the own immune system of the patient against the tumor cells. The immune checkpoint inhibitors can be used like anti-PD-1 or anti-PD-L1 antibodies that can reverse the immune suppression in the tumor microenvironment to enable T-cells to identify and kill cancer cells successfully.

Immunotherapy can be enhanced with targeted therapies to modify tumor microenvironment in a manner that boosts immune recognition. As an example, BRAF and MEK inhibitors in melanoma do not only suppress oncogenic signaling, but also enhance antigen presentation and immune cell infiltration in the tumors. These agents, with immune checkpoint inhibitors, can generate stronger and sustained anti-tumor effects than each treatment alone. Such synergy is able to enhance treatment efficacy but can also delay or overcome developed resistance which can be a frequent problem with monotherapy.

Moreover, tailored therapy may diminish immunosuppressive signaling in the tumor, establishing the environment that is more conducive to immune-mediated tumor destruction. The prospect of such combination strategies is especially high in the cancers in which immune evasion plays a significant role in the progression.

### Rationale for Combination Therapy

The rationale behind such a combination of targeted therapies and chemotherapy or immunotherapy is that this provides a multi-pronged attack on cancer, which improves therapeutic efficacy and tumor adaptability:

1. **Parallel inhibition of multiple signaling pathways:** It is not uncommon to find several keys signaling pathways on which tumors depend to grow, survive and proliferate. Combination therapies by hitting more than one of these pathways prevents tumor compensatory attempts by alternative survival pathways. Multi-targeted treatment enhances the possibility of disrupting tumor growth and attaining a more holistic treatment effect.

2. **Decrease in resistance formation:** Cancer cells are very flexible and may acquire resistance to single-agent therapy through activating alternative pathways or machinery. The combination therapies prevent more than one possible escape route at a time, making it highly unlikely that the cancerous cells will develop adaptive

ISBN: 978-81-985724-3-1


resistance. This assists in the longer-term effectiveness of treatment and may delay or prevent relapse.

3. **Greater clinical response:** Therapeutic modalities, including targeted agents with chemotherapy or immunotherapy, can be synergized together and result in more profound and sustained clinical response. This has a tendency to bring better results such as an increase in response rate, prolonged progression-free survival and, in a few instances, an increase in overall survival, which in the end results in patients having a more lasting and effective treatment protocol.

### Key Considerations and Challenges

Although combination therapies clearly have a potential, their application is fraught with a number of challenges:

- **Toxicity:** When a drug is combined with others, the side effects can be increased; these effects can be mild (such as fatigue, nausea), moderate, or severe (such as myelosuppression, organ toxicity). These effects are critical to put under close surveillance and supportive care.
- **Ideal sequencing and dosing:** The timing, sequence and dosage of each therapy may have a considerable impact. As an example, synergies could occur when they are given concurrently, yet there is a possibility that sequential therapy can reduce overlapping toxicities. Pharmacokinetic modeling and careful data of clinical trials are usually necessary to establish the most preferred regimen.
- **Patient selection:** Combination therapy will not be equally effective in all patients. The molecular profiling and biomarker testing are required to determine the patients most likely to be responsive to the treatment and subsequently the treatment can be tailored to the individual.

Although combination strategies are an effective way to overcome monotherapy limitations, it still needs thorough planning, a custom approach toward the patient and continuous monitoring in order to achieve maximum benefits and minimum risks.

ISBN: 978-81-985724-3-1


## REFERENCES


1. Saeed, R. F., Awan, U. A., Saeed, S., Mumtaz, S., Akhtar, N., & Aslam, S. (2023). Targeted therapy and personalized medicine. In *Therapeutic Approaches in Cancer Treatment* (pp. 177-205). Cham: Springer International Publishing.
2. Molla, G., & Bitew, M. (2025). The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted Therapies. *Journal of Molecular Pathology*, *6*(3), 20.
3. Couri, T., & Pillai, A. (2019). Goals and targets for personalized therapy for HCC. *Hepatology international*, *13*(2), 125-137.
4. Wang, M., Herbst, R. S., & Boshoff, C. (2021). Toward personalized treatment approaches for non-small-cell lung cancer. *Nature medicine*, *27*(8), 1345-1356.
5. Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., ... & Cervantes, A. (2020). Personalized medicine: recent progress in cancer therapy. *Cancers*, *12*(4), 1009.
6. Hoeben, A., Joosten, E. A., & van den Beuken-van Everdingen, M. H. (2021). Personalized medicine: recent progress in cancer therapy. *Cancers*, *13*(2), 242.
7. Pakkala, S., & Ramalingam, S. S. (2018). Personalized therapy for lung cancer: striking a moving target. *JCI insight*, *3*(15), e120858.
8. Wang, R. C., & Wang, Z. (2023). Precision medicine: disease subtyping and tailored treatment. *Cancers*, *15*(15), 3837.
9. Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018). Liver fibrosis: Direct antifibrotic agents and targeted therapies. *Matrix Biology*, *68*, 435-451.
10. Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020). Towards personalized treatment for early stage HER2-positive breast cancer. *Nature Reviews Clinical Oncology*, *17*(4), 233-250.
11. Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., ... & Calabrese, L. (2020). Moving towards personalized treatments of immune-related adverse events. *Nature reviews Clinical oncology*, *17*(8), 504-515.
12. Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., ... & Cheng, Q. (2022). Glioma targeted therapy: insight into future of molecular approaches. *Molecular cancer*, *21*(1), 39.

ISBN: 978-81-985724-3-1


13. Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., ... & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. *Cell*, *187*(7), 1617-1635.
14. Conrad, C., & Gilliet, M. (2018). Psoriasis: from pathogenesis to targeted therapies. *Clinical reviews in allergy & immunology*, *54*(1), 102-113.
15. Yen, T. T., Wang, T. L., Fader, A. N., Shih, I. M., & Gaillard, S. (2020). Molecular classification and emerging targeted therapy in endometrial cancer. *International Journal of Gynecological Pathology*, *39*(1), 26-35.